6533b7ddfe1ef96bd127524f
RESEARCH PRODUCT
Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist.
Natale D'alessandroSalvatore NovoDaniela Di LisiFrancesca Bonurasubject
Cardiovascular toxicityTime FactorsSettore MED/06 - Oncologia MedicaPharmacology toxicologyCardiologyAntineoplastic AgentsPharmacologyToxicologyMedical OncologyCardiotoxinsCardiovascular SystemProfessional RolePharmacovigilanceMedicineAnimalsHumansPhysician's RoleMolecular BiologyPharmacologyCardiotoxicitybusiness.industryCardiovascular toxicity Anthracyclines Tyrosine kinase inhibitors TrastuzumabSettore MED/11 - Malattie Dell'Apparato CardiovascolareAnticancer drugLaboratory PersonnelCardiovascular DiseasesSettore BIO/14 - FarmacologiaCardiology and Cardiovascular MedicinebusinessOncology drugsdescription
Both conventional and new anticancer drugs can frequently cause adverse cardiovascular effects, which can span from subclinical abnormalities to serious life-threatening and sometimes fatal events. This review examines the principal basic and clinical elements that may be of profit to identify, prevent and treat such toxicities. Clearly, the accomplishment of such objectives requires the strong commitment and cooperation of different professional figures including, but not limited to, pharmacologists, oncologists and cardiologists. The aspect of anticancer drug cardiotoxicity seems to be somehow underestimated, mainly due to inadequate reporting of adverse reactions from oncology drugs in the post-marketing setting. Thus, the implementation of pharmacovigilance is indispensable to rapidly and fully assess the safety of newer agents in real-life patients.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2011-09-06 | Cardiovascular toxicology |